| Axitinib Significantly Extended Progression?Free Survival Compared With ... - Medical News Today (press release) |
|
|
Medical News Today (press release) Pfizer today announced data from the pivotal Phase 3 AXIS 1032 trial, showing that in patients with previously treated advanced renal cell carcinoma (RCC), axitinib significantly extended progression?free survival (PFS) [HR=0.665, 95% CI; P<0.0001], |